Sengenics antibody biomarker profiling services allow users to identify and confirm new biomarkers and biomarker signatures with unparalleled reproducibility and specificity.
Overcoming a common challenge
Conventional array platforms use denatured proteins or protein fragments that are not correctly folded. More than 90% of antibody epitopes are known to be conformational; they identify the shape, not the amino acid sequence.
Protein fragments and peptides lack conformational epitopes and normally have vulnerable hydrophobic surfaces, leading to non-specific antibody binding. This generates non-specific hits that come with a low signal-to-noise ratio.
Using the patented KREX® protein folding technology, Sengenics arrays feature full-length, properly folded proteins. Conformational epitopes are retained, leading to highly specific hits, low background noise, and reproducible outcomes.
Image Credit: Sengenics
Discovery antigen panel
High-density profiling
Using the i-Ome® Antigen Panel, Sengenics could profile users’ liquid biopsy samples against over 1,600 autoimmune- and cancer-related antigens in a single assay. The panel has been made of an extensive range of human cellular proteins that belong to numerous classes. It is possible to detect IgG or IgA antibodies separately or concurrently for an expanded picture.
Image Credit: Sengenics
Cancer antigen panel
Profiling against cancer antigens
Using the CTA Antigen Panel, Sengenics could profile liquid biopsy samples against over 200 clinically appropriate cancer-testis antigens (CTA). Such tumor antigens are expressed normally in germ cells but not in adult somatic tissues.
As far as cancers are concerned, CTA expression could be interrupted leading to their existence in tumors and following recognition by the immune system. Users can detect IgG or IgA antibodies to these antigens individually or concurrently for an expanded picture.
Image Credit: Sengenics
Autoimmune disease antigen panel
Autoimmune disease antibody screening
Using the Pan-Autoimmune Antigen Panel, Sengenics could profile liquid biopsy samples against over 100 clinically applicable antigens linked to an extensive array of autoimmune diseases, such as RA, SLE, Sjogren’s, and diabetes among numerous others. Detect IgG or IgA antibodies to such antigens individually or simultaneously for an expanded picture.
Image Credit: Sengenics